Improving anti-angiogenic therapy via selective delivery of cationic liposomes to tumour vasculature.
In the past three decades, two very important findings regarding tumour vasculature have been made. Firstly, it has been known a solid tumour has to establish an adequate blood supply to grow beyond a critical mass. Secondly, it has been proven that the tumour vasculature is relatively more aberrant, dynamic and permeable than healthy host tissue. This review discusses the potential of delivering therapeutic nucleic acids to tumour vasculature using cationic liposomes, vehicles recently demonstrated to be selectively delivered to tumour vasculature.
Dass
Crispin R
CR
Johnson & Johnson Research, Box 4555, Strawberry Hills 2012, Australia. crispin.dass@genetype.com.au
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D000818:Animals; D002412:Cations / Q000378:metabolism; D002626:Chemistry, Pharmaceutical; D004337:Drug Carriers; D016503:Drug Delivery Systems; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D006801:Humans; D008081:Liposomes / Q000008:administration & dosage* / Q000737:chemistry; D009389:Neovascularization, Pathologic / Q000378:metabolism / Q000628:therapy*
D020533:Angiogenesis Inhibitors; D002412:Cations; D004337:Drug Carriers; D008081:Liposomes